Air T (AIRT) director acquires 1,000 options exercisable 08/06/2026
Rhea-AI Filing Summary
Peter B. McClung, a director of Air T Inc. (AIRT), reported the acquisition of two option grants on 08/11/2025. Each grant covers 500 stock options: one with a $30 exercise price and one with a $50 exercise price. Both option series become exercisable on 08/06/2026 and expire on 08/06/2045. Following the reported transactions, Mr. McClung directly beneficially owns 500 shares tied to each grant (totaling 1,000 underlying shares reported here); the filing notes that, after prior expirations, the company currently has 1,500 options outstanding tied to earlier grants and that some earlier options are unexercisable pending future stock-price tests described in the company proxy.
Positive
- Clear disclosure of option grants with exercise prices ($30 and $50), exercisable date (08/06/2026), and expiration (08/06/2045)
- Director participation through compensation-aligned instruments that tie value to future stock performance
Negative
- None.
Insights
TL;DR: Director acquired 1,000 options with multi-year exercise windows and long-dated expirations, showing insider option grants rather than open-market purchases.
The filing documents two option acquisitions by a director on the same date: 500 options at a $30 strike and 500 at a $50 strike, both exercisable in August 2026 and expiring in August 2045. These are option grants (transaction code A), not open-market buys, so they reflect compensation or award activity. The long 20-year contractual term is notable but not uncommon for certain equity incentive plans. The disclosure that some prior options are subject to price-tranche vesting and that total outstanding after expirations is 1,500 provides useful context on the company's option overhang and vesting structure.
TL;DR: The report is a routine insider grant disclosure with governance-relevant vesting conditions tied to stock-price hurdles.
Details show the director received option awards with explicit exercisability and expiration dates; the explanatory note reveals earlier grants include price-tranche vesting tied to market-price tests and that failures to meet thresholds cause immediate expirations. That structure links management upside to share-price performance but also creates the potential for expirations if price thresholds are not met. Investors can reference the company proxy for full vesting mechanics and potential dilution implications.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock options | 500 | $0.00 | $0.00 |
| Grant/Award | Stock options | 500 | $0.00 | $0.00 |
Footnotes (1)
- F1. Cumulative amount does not include presently unexerciseable options granted in December 2020. Whether any of the unexerciseable options vest, and the amount that does vest, is tied to various price tranches (six per year) corresponding to future testing dates (June 30 of each year) and the achievement of our Common Stock trading at or above the exercise price for each applicable price tranche. In the event that the market price of our common stock does not reach or exceed the exercise price during the 60 days immediately preceding the applicable price tranche, 100% of the applicable options associated with that price tranche expire immediately. After expirations due to failures to reach the prior stated exercise prices, total amount currently outstanding is 1,500. For further details, see the Company's proxy statement filed July 3, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
